CJC 1295 With DAC 2mg

CJC-1295 with DAC (also known as DAC:GRF or CJC-1295 DAC) is a long-acting synthetic analog of Growth Hormone-Releasing Hormone (GHRH). This 29-amino-acid peptide features a Drug Affinity Complex (DAC) modification that binds to albumin in the bloodstream, dramatically extending its half-life to approximately 6–8 days (based on human studies), enabling sustained elevation of endogenous growth hormone (GH) and IGF-1 levels.

Key Benefits and Potential Uses

CJC-1295 with DAC is primarily investigated in research for prolonged GH stimulation:

• Supporting increased lean muscle mass, protein synthesis, and strength gains.
• Promoting fat loss, particularly visceral and stubborn adipose tissue reduction.
• Enhancing recovery from exercise, training, or injury with improved tissue repair and reduced inflammation.
• Improving sleep quality, energy levels, skin elasticity, and overall vitality.
• Contributing to better body composition, bone density, and potential anti-aging effects through sustained IGF-1 elevation.
• Often used in protocols aiming for consistent, elevated GH/IGF-1 levels over days rather than short pulses.

It functions by:

• Mimicking endogenous GHRH to stimulate pituitary GH secretion in a sustained, dose-dependent manner.
• Producing prolonged increases in plasma GH (2- to 10-fold for 6+ days) and IGF-1 (0.5- to 3-fold for 9–11 days or longer with multiple doses).
• Providing a more continuous GH profile compared to shorter-acting GHRH analogs.

This extended action makes it convenient for less frequent dosing while maintaining elevated anabolic signaling.

Administration Options

Typically supplied as lyophilized powder in vials (e.g., 2mg, 5mg, or 10mg) for reconstitution with bacteriostatic water. Administered via subcutaneous injection. In research settings, dosing often ranges from 1–2 mg per week (or 30–60 mcg/kg body weight), split into 1–2 injections weekly due to the long half-life. Protocols may involve cycling or steady use.